Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Treasury Shares: 2023-2025

Historic Treasury Shares for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $1.3 million.

  • Compass Therapeutics' Treasury Shares fell 65.14% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 65.14%. This contributed to the annual value of $3.8 million for FY2024, which is 151.07% up from last year.
  • As of Q3 2025, Compass Therapeutics' Treasury Shares stood at $1.3 million, which was down 56.57% from $2.9 million recorded in Q2 2025.
  • Compass Therapeutics' 5-year Treasury Shares high stood at $3.8 million for Q4 2024, and its period low was $1.3 million during Q3 2025.
  • Its 3-year average for Treasury Shares is $2.6 million, with a median of $2.9 million in 2025.
  • In the last 5 years, Compass Therapeutics' Treasury Shares soared by 151.07% in 2024 and then tumbled by 65.14% in 2025.
  • Over the past 3 years, Compass Therapeutics' Treasury Shares (Quarterly) stood at $1.5 million in 2023, then surged by 151.07% to $3.8 million in 2024, then tumbled by 65.14% to $1.3 million in 2025.
  • Its Treasury Shares stands at $1.3 million for Q3 2025, versus $2.9 million for Q2 2025 and $2.9 million for Q1 2025.